+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 45Years
FEMALE
ID06449651

Evaluating Nipocalimab Versus Placebo to Reduce Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-Risk Pregnant Women

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

39

Participants Needed

21

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of nipocalimab compared with placebo to reduce the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT in pregnant women who have had previous pregnancies affected by this condition. This phase 3 study focuses on at-risk pregnancies where the fetus is confirmed to have a specific platelet antigen, and the mother has antibodies against it. The goal is to assess whether nipocalimab can lower the risk of severe bleeding, low platelet counts, or death in the fetus or newborn. Participants will be randomly assigned to receive either nipocalimab or a placebo intravenously during pregnancy, between weeks 13 and 18 of gestation. The study is double-blind, so neither participants nor researchers know which treatment is given. Maternal health and fetal status will be closely monitored throughout pregnancy and up to 24 weeks postpartum. The study also tracks adverse events, antibody responses, and infant development up to 104 weeks after birth. Participants will undergo assessments including physical exams, medical history reviews, vital signs, ECGs, and laboratory tests at screening and during the study. Researchers will measure outcomes such as the occurrence of severe bleeding, platelet counts at birth, need for platelet transfusions, and infant development using the Bayley Scales at 52 and 104 weeks. Safety is monitored for both mothers and infants throughout the study period, which lasts until approximately two years after birth.

CONDITIONS

Brief Title

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here